Laboratórios virtuais: O desenvolvimento de um protótipo para o ensino da química

Como proposta para o presente trabalho, propomos um protótipo de laboratório virtual para o ensino de química, com base nas boas práticas presentes na literatura. O trabalho qualitativo e empírico descritivo segue a metodologia de desenvolvimento de um protótipo, e foi desenvolvido no Departamento de Estatística e Informática da Universidade Federal Rural de Pernambuco, e foi desenvolvido no período de maio de 2016 a maio de 2017.

A computação na sociedade palestina: Um estudo de caso

Como proposta para o presente estudo, destacamos um estudo de caso comparativo de utilização de recursos tecnológicos no sistema educacional Autoridade Nacional Palestina. O trabalho qualitativo e empírico descritivo foi desenvolvido no Departamento de Estatística e Informática da Universidade Federal Rural de Pernambuco (Brasil), no período de fevereiro a maio de 2017.

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Photosynthetic characteristics in fig tree accessions for diversification of production

Photosynthesis allows plants, through metabolic reactions, to obtain products for their growth and development. Knowledge of and estimating the physiological variables involved in the photosynthetic process can be an advantage in choosing accessions for setting up an orchard. The aim of this study therefore was to evaluate some of the physiological characteristics involved in the photosynthetic process of six commercial accessions of the fig tree. The experiment was conducted in a completely randomised design, comprising six treatments and six replications, giving a total of 36 experimental units. The treatments consisted of the following fig accessions: ‘Roxo de Valinhos’, ‘Palestino’, ‘Figo Vermelho’, ‘PI 189’, ‘Cuello Negro’ and ‘Turco’. The net rate of CO2 assimilation, stomatal conductance, transpiration rate and internal leaf temperature varied statistically between accessions. Some accessions demonstrated the same performance as ‘Roxo de Valinhos’ for the photosynthetic variables. As such, the dependence of the domestic market on one single cultivar should be reviewed; however, further studies on other physiological and production characteristics should be carried out in order to validate each recommendation

Numerical and physical simulation of steel ladle draining operation with different well block design.

At the end of a ladle draining operation a structure called drain sink forms at the top surface of the liquid steel allowing slag carry over from the ladle to the tundish and causing metallic losses. On this study, the effect of different well block configuration on the critical height for drain sink formation (HC) was investigated using numerical and physical modeling. The modified well block configuration showed lower HC in most of the cases when compared with the standard design. It could represent almost 50% of metallic lost savings during the continuous casting process. Air injection was also investigated and increased significantly the HC value. The numerical model showed good agreement with the physical model and was used to help undertanding this behavior

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups. Methods: Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed. Results: Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension. Interpretation: Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019